RxDoctor Payments Data

Naomi Peters, PA

Physician Assistant · Covington, LANPI 1073284535

Payments from drug & device makers

$1,599in general payments, 2019–2025

Across 64 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$287
  • Kestra Medical Technology Services, Inc.$172
  • Irhythm Technologies, Inc.$152
  • Abbott$149
  • AstraZeneca$119
  • Sanofi-aventis U.S. LLC$98
  • plus $622 from 14 others

What the payments were for

  • Food & beverage$1,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,599 in reported general payments places this provider in the 75th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,425
Medicare patients
133
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$96,145
EntrestoSacubitril/Valsartan40$37,456
XareltoRivaroxaban15$16,418
Metoprolol Succinate240$2,295
Ranolazine ErRanolazine11$1,028
ClopidogrelClopidogrel Bisulfate106$1,014
Carvedilol93$1,001
Rosuvastatin Calcium86$999
Valsartan44$991
Atorvastatin Calcium81$917
Flecainide Acetate15$820
Amiodarone Hcl28$761
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$754
Pantoprazole Sodium52$593
Pravastatin Sodium12$511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$96,14596 claims
NovartisEntresto$79$37,45640 claims
Johnson & JohnsonXarelto$31$16,41815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →